

PRESS RELEASE

Prof David Livermore joins the advisory board of BioVersys

Basel, 1st October 2013

BioVersys is proud to announce that with Professor David Livermore, a world-renowned antibiotics expert is joining its scientific advisory board. Professor Livermore is a key opinion leader on the subject of antibiotic resistance and advises several governmental agencies on resistance developments and healthcare measures.

David Livermore gained his BSc in 1978 and his PhD in 1983 from the University of London, UK. He worked at the London Hospital Medical College from 1980 until 1997 when he joined the Health Protection Agency (now Public Health England), becoming Director of its Antibiotic Resistance Monitoring and Reference Laboratory in 1998. In October 2011 he became Professor of Medical Microbiology at the University of East Anglia but with 30% of this time supplied back to Public Health England as its Lead on Antibiotic Resistance. He has broad interests on the evolution and dissemination of antibiotic resistance and its relationship to antibiotic prescribing. Prof Livermore sits on the British Society for Antimicrobial Chemotherapy's working parties on resistance surveillance, multi-resistant pathogens and susceptibility testing and on its Antibiotic Action advisory board. He also is a member of the UK Government's Antimicrobial Resistance & Healthcare Infections Advisory Committee. He publishes and speaks widely on resistance and has edited for several journals including Journal of Antimicrobial Chemotherapy, Journal of Medical Microbiology and, currently, International Journal of Antimicrobial Agents.

"Our already strong scientific advisory board is receiving a further boost by welcoming Professor David Livermore and we are proud that our technology and our team were able to attract him to BioVersys." says Dr. Marcel Tigges, CSO of BioVersys.

Contact: Dr. Marc Gitzinger, CEO, Tel. +41 61 633 2250, marc.gitzinger@bioversys.com

BioVersys AG is a privately held biopharmaceuticals company. It is a spin-off company from the ETH Zurich located in Basel. The company focuses on the research and development of new drugs and compounds, which switch off drug resistance within bacterial pathogens and thus restore the efficacy of existing antibiotics. The Team and the technology of BioVersys have already received multiple awards, such as Venture Kick, the Heuberger Winterthur Jungunternehmerpreis 2009, the Swiss TB Award, the Life Sciences Prize 2011, the Swiss Technology Award 2011 and the Jungunternehmerpreis Nordwestschweiz 2012. (www.bioversys.com)